Enanta Pharmaceuticals (NASDAQ:ENTA) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.35) by 5.93 percent. This is a 4.1 percent decrease over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $20.32 million which missed the analyst consensus estimate of $22.86 million by 11.12 percent. This is a 13.82 percent decrease over sales of $23.57 million the same period last year.
SuperCom Announces Pricing Of $2.75M Public Offering Of 3,235,295 Units At A Price Of $0.85/Unit
SuperCom (NASDAQ:SPCB) ("SuperCom" or the "Company"), a global provider of secured solutions for the e-Government, IoT and Cybersecurity sectors, today announced the pricing of its public
